Pharming Turns A Profit After Reclaiming Ruconest

Pharming Group, a company that has been on the drug development scene since the ‘80s, has recorded a quarterly net profit for the first time – two years earlier than previously forecast.

SC1805_Plant Graph_554080540 _1200.jpg
Pharming sees growth and first quarterly profit • Source: Shutterstock

Pharming Group NV has seen its first quarterly net profit in 2018 driven by sales of Ruconest – its own drug to which the company bought back the rights in 2016.

In Q1 2018, Pharming saw a net profit of €3.3m flow in from sales of Ruconest (conestat alfa). In the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business